It has been shown that bufalin may target both RIPK3 and MLKL, thereby leading to necroptosis and the subsequent proliferation inhibition of GBM and TNBC cells (Li et al., 2018; LingHu et al., 2020). Here, RIPK3 is linked to glioblastoma.